Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -26.80M | -26.57M | -21.66M | -22.41M | -20.84M |
| Total Depreciation and Amortization | 165.10K | 179.60K | 188.40K | 186.70K | 184.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.02M | 7.60M | 4.01M | 3.80M | 2.42M |
| Change in Net Operating Assets | -703.80K | -280.50K | 1.54M | 2.00M | -404.40K |
| Cash from Operations | -18.32M | -19.07M | -15.92M | -16.42M | -18.64M |
| Capital Expenditure | -15.60K | -19.10K | -17.50K | -17.60K | -47.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -15.60K | -19.10K | -17.50K | -17.60K | -47.60K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -41.40K | -41.40K | -50.60K | -55.20K | -55.20K |
| Issuance of Common Stock | 21.53M | 177.50K | 177.50K | 90.20K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.65M | -- | -- | -- | -- |
| Cash from Financing | 13.46M | 100.10K | 93.20K | 25.80K | -41.00K |
| Foreign Exchange rate Adjustments | 1.36M | 861.20K | 399.40K | 920.20K | 557.90K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.51M | -18.13M | -15.45M | -15.49M | -18.17M |